会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 33. 发明授权
    • Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIA inhibitors
    • 芳基丙酰胺,芳基丙烯酰胺,芳基丙酰胺或芳基甲基脲类似物作为因子XIA抑制剂
    • US08410155B2
    • 2013-04-02
    • US12518111
    • 2007-12-13
    • Donald J. P. Pinto
    • Donald J. P. Pinto
    • A61K31/417A61K31/4174A61K31/4412A61K31/513C07D233/64C07D239/28C07D213/24C07D213/62
    • C07D403/12C07D401/12C07D403/14
    • The present invention provides compounds of Formula (I) or (II): or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L1, R3, R4, R8a, R11 and M are as defined herein. The compounds of Formula (I) or (II) are selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    • 本发明提供式(I)或(II)的化合物:或其立体异构体,互变异构体,药学上可接受的盐或溶剂化物形式,其中变量A,L1,R3,R4,R8a,R11和M如本文所定义。 式(I)或(II)的化合物是凝血级联和/或接触激活系统的丝氨酸蛋白酶的选择性抑制剂; 例如凝血酶,因子Xa,因子XIa,因子IXa,因子VIIa和/或血浆激肽释放酶。 特别地,它涉及作为选择性因子XIa抑制剂或fXIa和血浆激肽释放酶的双重抑制剂的化合物。 本发明还涉及包含这些化合物的药物组合物和使用其制备血栓栓塞和/或炎症性疾病的方法。